Antiplatelet Therapy in Hemorrhagic Stroke Patients

Introduction to Antiplatelet Therapy

The American College of Chest Physicians recommends that antiplatelet therapy should generally be avoided long-term in patients with a history of hemorrhagic stroke and angioplasty, unless there is a high risk of thromboembolic events (>7% per year) and the patient has a relatively low risk of recurrent intracerebral hemorrhage 1, 2

Risk Assessment Framework

Patients with mechanical heart valves have a high thromboembolic risk (>7% per year), according to the American College of Chest Physicians 2
A high CHADS₂ score (≥4 points) is associated with a high thromboembolic risk (>7% per year), as stated by the American College of Chest Physicians 2
Recent carotid or coronary stenting (especially within 1-3 months) is a factor favoring antiplatelet resumption, as recommended by the American College of Cardiology 3
Deep hemorrhages are associated with a higher risk of recurrence, according to the American College of Chest Physicians 2
Cerebral amyloid angiopathy is associated with a very high risk of recurrent bleeding, as stated by the American College of Cardiology 3
Lobar hemorrhage location is associated with a higher risk of recurrence, according to the American Heart Association 4
Multiple microbleeds on MRI are associated with a higher risk of recurrence, as stated by the American Heart Association 4

Timing Recommendations

The American College of Cardiology recommends continuing P2Y12 inhibitor (clopidogrel preferred) after carotid stenting within the previous 1-3 months 3
The American College of Cardiology suggests considering stopping aspirin if dual therapy was being used after carotid stenting within the previous 1-3 months 3
The American College of Cardiology recommends considering stopping all antiplatelet therapy after standard DAPT duration ends (usually 1-3 months post-stenting) 3
The American College of Chest Physicians and the American Heart Association recommend considering resuming antiplatelet monotherapy only after ICH has stabilized in patients with very high thromboembolic risk (e.g., mechanical heart valves, CHADS₂ score ≥4) 2, 4
The American Heart Association recommends waiting at least several days from ICH onset before resuming therapy in patients with very high thromboembolic risk 4

Important Considerations

The American College of Chest Physicians and the American Heart Association recommend avoiding dual antiplatelet therapy after hemorrhagic stroke due to significantly increased bleeding risk 2, 4

Special Situations

The International Journal of Stroke recommends consulting with the interventionalist/surgeon to determine the appropriate antiplatelet strategy for patients with a history of hemorrhagic stroke requiring carotid intervention 5
The International Journal of Stroke suggests considering aspirin monotherapy rather than dual antiplatelet therapy if carotid endarterectomy is planned urgently 5
The American College of Cardiology recommends stopping all antiplatelet therapy when considered safe from post-operative bleeding risk (typically 3-14 days after surgery) in patients who had carotid endarterectomy 3

Common Pitfalls to Avoid

The American Heart Association recommends avoiding automatically restarting antiplatelet therapy after hemorrhagic stroke without careful risk assessment 4
The American Heart Association recommends avoiding prolonged dual antiplatelet therapy in patients with a history of ICH (significantly increases bleeding risk) 6
The American College of Chest Physicians and the American Heart Association recommend considering the location of hemorrhage (lobar hemorrhages have higher recurrence risk than deep hemorrhages) when making decisions about antiplatelet therapy 2, 4

Antiplatelet Therapy After Intracerebral Hemorrhage

Introduction to Antiplatelet Therapy

The American Heart Association and other guideline societies recommend resuming antiplatelet therapy after intracerebral hemorrhage (ICH) has stabilized, typically waiting at least several days from ICH onset, with the optimal timing individualized based on thromboembolic risk versus bleeding risk assessment in patients with a history of multiple infarcts 7

Risk Stratification and Management

Patients with multiple prior infarcts are considered to have high thromboembolic risk, and resumption of antiplatelet monotherapy is reasonable after the hemorrhage has stabilized 7
The RESTART trial showed no significant difference in recurrent ICH between starting versus avoiding antiplatelet therapy, though the study was underpowered, with a hazard ratio of 0.51 (95% CI 0.25-1.03) 7

Evidence-Based Treatment

Current guidelines indicate that resuming antiplatelet therapy beyond 24 hours after ICH symptom onset may be reasonable for prevention of thromboembolic events, with a Grade B evidence level across multiple international guidelines (Canadian, American, UK, Chinese) 7
Aspirin 75-100 mg daily and clopidogrel 75 mg daily are preferred agents for monotherapy, with either agent being acceptable and clopidogrel having slightly lower gastrointestinal bleeding risk 8

Ongoing Research and Future Directions

The ASPIRING trial aims to recruit 4,148 ICH survivors to definitively establish timing and effects of antiplatelet resumption, with results expected to provide Level A evidence 9, 10

Management of Antiplatelet Therapy After Hemorrhagic and Ischemic Stroke

Risk Assessment and Stratification

The American Heart Association recommends that patients with lobar hemorrhage location are at higher risk of recurrence than those with deep hemorrhages, and this should be considered when deciding on antiplatelet resumption 11
Elderly patients with lobar ICH are at higher risk of amyloid angiopathy, which should be taken into account when assessing the risk of recurrent bleeding 11

Timing of Antiplatelet Resumption

For patients with very high thromboembolic risk (>7%/year), antiplatelet monotherapy can be resumed after the intracerebral hemorrhage has stabilized, typically at 7-10 days after ICH onset if the hemorrhage has stabilized, as recommended by the American Heart Association 11
The American Heart Association suggests that antiplatelet monotherapy is reasonable for patients with stabilized ICH and compelling indications, typically beyond 4 weeks after ICH onset 11

Hemorrhagic Transformation and Primary ICH

The American Heart Association notes that hemorrhagic transformation within an ischemic stroke has a different natural history than primary ICH, and continuing anticoagulation may be reasonable in hemorrhagic transformation if there is compelling indication and the patient is not symptomatic from the transformation 11

Guideline Recommendations

The American Heart Association/American Stroke Association guidelines (2011 and 2021) provide Class IIa-IIb evidence (Level B-C) for the management of antiplatelet therapy after hemorrhagic and ischemic stroke, recommending careful risk-benefit assessment and individualized decision-making 11, 12
The upcoming results of the ASPIRING trial are expected to provide definitive Level A evidence on the timing and safety of antiplatelet resumption after ICH, with 4,148 patients recruited 13

Restarting Antiplatelet Therapy After Hemorrhagic Transformation

Evidence-Based Recommendations

The American Heart Association recommends antiplatelet monotherapy for patients with stabilized intracerebral hemorrhage (ICH) and compelling indications, typically beyond 4 weeks, but can be considered as early as 7-10 days for high thromboembolic risk patients 14
The RESTART trial demonstrated that antiplatelet resumption did not increase recurrent ICH risk (adjusted HR 0.51, 95% CI 0.25-1.03) in patients with primary ICH, suggesting that earlier resumption may be appropriate for hemorrhagic transformation cases 14

Medication Selection and Timing

Antiplatelet monotherapy can be safely resumed at 7-10 days after hemorrhagic transformation if the hemorrhage has stabilized, with aspirin 75-100 mg daily or clopidogrel 75 mg daily as preferred agents 14

Antiplatelet Resumption After Acute Ischemic Stroke With Subacute Intracerebral Hemorrhage

Timing Recommendations

In patients with very high thromboembolic risk (e.g., CHADS₂ ≥ 4, mechanical heart valve, or recent coronary/carotid stent within 1–3 months), aspirin monotherapy (75–100 mg daily) may be started 7–10 days after ICH onset provided repeat brain imaging shows hemorrhage stability; this guidance comes from the 2023 American Heart Association/American Stroke Association (AHA/ASA) guidelines, which note limited supporting data and therefore assign a weak/low‑strength recommendation. 15
Do not restart aspirin at 24–48 hours after ICH onset for most patients, because the presence of intracerebral hemorrhage substantially raises bleeding risk; this precaution is based on a 2007 Circulation publication that reflects moderate‑quality evidence. 16

Guideline Uncertainty

The 2023 AHA/ASA stroke guidelines state that strong recommendations regarding antiplatelet agents after intracerebral hemorrhage cannot be made due to ongoing uncertainties, indicating a low level of evidence for any specific timing or choice of agent. 17

Antiplatelet Management After Intracerebral Hemorrhage

Immediate Management

Discontinue all antiplatelet agents immediately upon diagnosis of intracerebral hemorrhage and reverse any coagulopathy – recommended for any patient presenting with ICH to limit ongoing bleeding. Evidence level: expert consensus (Stroke 2011) 18
Obtain urgent neurosurgical consultation to evaluate hematoma stability and need for operative intervention – essential for all ICH patients regardless of antithrombotic history. Evidence level: expert consensus (Stroke 2011) 18

Hemorrhagic Transformation of Ischemic Stroke

If a patient experiences asymptomatic hemorrhagic transformation of an ischemic stroke and has a compelling indication for antiplatelet therapy, continuation of antiplatelet monotherapy may be reasonable – the drug can be resumed after confirming radiologic stability (≈7–10 days). Evidence level: expert consensus (Stroke 2011) 18

Clinical Trial Evidence

The RESTART trial (2019) demonstrated that resuming antiplatelet therapy after ICH did not increase the risk of recurrent hemorrhage (adjusted HR 0.51, 95 % CI 0.25–1.03, p = 0.060) and may even reduce it – highest‑quality evidence supporting early antiplatelet re‑initiation. Evidence level: high‑quality randomized trial 19

Guideline Consensus

American Heart Association, Canadian Stroke Guidelines, UK/Ireland Stroke Guidelines, and Chinese Stroke Guidelines classify antiplatelet use after ICH as Level B evidence and state that antiplatelet agents “may be considered” or are “reasonable” in patients with prior antithrombotic indication – reflects moderate‑quality evidence and expert agreement. Evidence level: Level B (moderate) 20, 21

Ongoing Research

The ASPIRING trial is enrolling approximately 4,150 survivors of ICH to generate definitive Level A evidence on optimal timing and safety of antiplatelet therapy after hemorrhage – results are anticipated to clarify subgroup‑specific recommendations. Evidence level: prospective multicenter trial (Level A pending) 22, 20